Dr Andre on the Efficacy of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC Subgroups

Thierry Andre, MD, discusses subgroup and safety analyses of the phase 3 CheckMate 8HW trial of frontline nivolumab plus ipilimumab in MSI-H/dMMR mCRC.

Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital, discusses findings from subgroup and safety analyses of the phase 3 CheckMate 8HW trial (NCT04008030), which investigated nivolumab (Opdivo) plus ipilimumab (Yervoy) vs chemotherapy in the frontline setting in patients with microsatellite instability–high (MSI-H), mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC).